Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate

Eskandarynasab, Maryam; Doustimotlagh, Amir Hossein; Takzaree, Nasrin; Etemad‐Moghadam, Shahroo; Alaeddini, Mojgan; Dehpour, Ahmad Reza; Goudarzi, Ramin; Partoazar, Alireza

doi:10.1016/j.lfs.2020.118033

Cited by 7 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liposome formulation can enhance oral bioavailability through protection from harsh conditions as well as better absorption across the GI tract (Daeihamed et al, 2017). We have shown previously that administration of PSL alone or in combination with AL had a robust osteoprotection against MP‐induced osteoporosis in rats (Eskandarynasab, Doustimotlagh, et al, 2020). It was confirmed that PS molecules involve in bone mineralization and building (Cho et al, 2013; Xu et al, 2013).…”

Section: Discussionmentioning

confidence: 89%

“…In this experiment, osteoporosis was induced in male Wistar rats (200–230 g) by oral administration (gavage) of MP 10 mg/kg daily for 3 weeks (Eskandarynasab, Doustimotlagh, et al, 2020). The subeffective doses of PSL and Cur were selected at 20 and 25 mg/kg, respectively, and the treatments continued for 3 weeks.…”

Section: Methodsmentioning

confidence: 99%

“…Four‐micrometer‐thick sections were cut and stained with hematoxylin/eosin. Trabecular bone thickness, cortical bone thickness, cortical area, and trabecular number per millimeter trabecular surface were measured on the cancellous bone of the metaphysis section at a 195‐μ distance from the growth plate in 20 fields (Eskandarynasab, Doustimotlagh, et al, 2020). The samples were examined by two special pathologists without information on the experimental groups.…”

Section: Methodsmentioning

confidence: 99%

“…However, the low bioavailability of curcumin (Cur) due to its poor absorption, rapid metabolism, and fast systemic elimination limits its benefits. This deficit has led to the development of numerous novel formulations and delivery systems to overcome this problem (Anand et al, 2007) It was revealed that liposomal anti-osteoporotic drugs could enhance the stability and bioactivity of the drugs (Epstein et al, 2008) as well as therapeutic efficacy in a GCS-induced osteoporosis model (Eskandarynasab, Doustimotlagh, et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, long‐term bisphosphonate therapy can lead to severe adverse effects such as atypical femoral fractures (AFFS), osteonecrosis of the jaw (ONJ), AND esophageal cancer (Reyes et al, 2016). Turning to natural products such as curcumin (Cur) or phosphatidylserine combined with the existing anti‐osteoporotic drugs is recommended in order to reduce the adverse effects of drug usage in the long term (An et al, 2016; Eskandarynasab, Doustimotlagh, et al, 2020; Eskandarynasab, Etemad‐Moghadam, et al, 2020; Kim et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Phosphatidylserine liposomes containing curcumin inhibit bone loss in osteoporotic rats: A possible synergy through a common signaling pathway

Partoazar

Goudarzi²

2022

Journal of Food Biochemistry

Self Cite

View full text Add to dashboard Cite

The present study aimed to investigate the effect of phosphatidylserine liposomes containing curcumin (PSLs-Cur) on the development of osteoporosis induced by glucocorticoids (GCs) in the rat model. PSL-Cur, phosphatidylserine (PSL), curcumin (Cur), and alendronate (AL) drugs as a positive control were administrated orally to evaluate the beneficial effects of 3-week treatments on osteoporotic rats. The biochemical and biomechanical properties of bone parameters as well as gene expression were evaluated in treated rats. Moreover, histomorphometric examinations were performed on the bone tissues of the animals. The results revealed that PSL-Cur oral administration caused a significant improvement in serum markers, mechanical strength, and OPG gene expression rather than PSL or Cur administration in osteoporotic rats. Also, PSL-Cur significantly increased the thickness and volume of cortical and trabecular bone mass in comparison with the untreated osteoporotic group. The results of this study indicated that PSL-Cur had a more inhibitory effect on bone loss induced by GCs compared to AL standard drug. Our findings suggested that PSL-loaded Cur may be an appropriate alternative therapy for glucocorticoid-induced osteoporosis. Practical applicationsOsteoporosis is one of the most serious metabolic chronic diseases that causes fragile bone due to decreased mineral density and microarchitectural deterioration in humans. The osteoprotective effects of curcumin and phosphatidylserine, as a food spice and supplementary diet, respectively, have been shown, previously. However, the low bioavailability of curcumin (Cur) due to its poor absorption, rapid metabolism, and fast systemic elimination, limits its benefits. This deficit can be modified with phosphatidylserine liposome (PSL) formulation that facilitates the gastrointestinal delivery of Cur. Moreover, PSL is known as an osteoprotective agent that may make synergy effect with Cur against GC-induced osteoporosis. In this study, daily oral administration of phosphatidylserine liposomes containing curcumin (PSL-Cur) for 3 weeks, considerably improved biochemical, biomechanical, and gene expression of bone parameters in the treated animals subjected to osteoporosis. PSL-Cur can significantly increase the thickness and volume of cortical and trabecular bone mass as well as the mechanical bone strength in animals. Experimental findings proposed

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Phosphatidylserine liposomes containing curcumin inhibit bone loss in osteoporotic rats: A possible synergy through a common signaling pathway

Partoazar

Goudarzi²

2022

Journal of Food Biochemistry

Self Cite

View full text Add to dashboard Cite

show abstract

The role of bacterial infections in rheumatoid arthritis development and novel therapeutic interventions: Focus on oral infections

Afrasiabi

Chiniforush

Partoazar

et al. 2023

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an inflammatory joint disease, with an overall prevalence of 0.46% worldwide. 1 The disease is characterized by bone erosion, loss of articular cartilage, chronic synovial inflammation, causing joint pain, swelling, stiffness, and disability in performing physical functions. 2,3 Although all joints are subject to the disease, RA usually affects the joints of the feet, knees, and hands. 4 The clinical manifestations of RA are usually not limited to joints but can turn into a systemic disorder involving the blood vessels, kidneys, lungs, heart, and liver. Furthermore, RA patients may suffer from nonspecific complications such as weight loss, fatigue, and malaise. 5 The presence of either rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPAs) has usually been used as the hallmark of RA. 6 This disease is multifactorial lying on genetic as well as environmental factors triggering its pathogenesis. 7 Environmental factors such as obesity and diet, smoking, infections, and microbiota have been recognized as risk factors to develop RA in the predisposed population. 8 HLA and some non-HLA genes were also associated with susceptibility to RA. It was established that HLA alleles HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*13, and DRB1*15 are linked to RA susceptibility. 9Infections have long been known as a main player in the pathogenesis of RA. Some of the pathogens can involve multiple routes

show abstract

New concepts in wound targeting through liposome-based nanocarriers (LBNs)

Partoazar

Kianvash

Goudarzi³

2022

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate

Cited by 7 publications

References 38 publications

Phosphatidylserine liposomes containing curcumin inhibit bone loss in osteoporotic rats: A possible synergy through a common signaling pathway

Phosphatidylserine liposomes containing curcumin inhibit bone loss in osteoporotic rats: A possible synergy through a common signaling pathway

The role of bacterial infections in rheumatoid arthritis development and novel therapeutic interventions: Focus on oral infections

New concepts in wound targeting through liposome-based nanocarriers (LBNs)

Contact Info

Product

Resources

About